{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:28:43Z","timestamp":1783164523063,"version":"3.54.6"},"reference-count":38,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>This study aimed to elucidate visual benefits of ranibizumab in patients with neovascular age-related macular degeneration (nAMD) compared with control arms and identify factors affecting response.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a post-hoc pooled analysis of two phase III studies, ANCHOR and MARINA, of ranibizumab for the treatment of nAMD. ANCHOR included 83 international sites. MARINA included 96 sites in the USA. Analysis included patients (control, n=323; ranibizumab, n=332) with nAMD and a baseline best-corrected visual acuity (BCVA) of \u226535\u2013&lt;85 letters.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients receiving ranibizumab achieved an adjusted mean BCVA superiority of 18.9 and 21.2 letters over 12 and 24 months, respectively, compared with control. Ranibizumab treatment, higher baseline BCVA, lower age and smaller lesion size were positively associated with the ability to achieve BCVA &gt;69 letters. Patients with the highest baseline BCVA had lowest BCVA gains. Ranibizumab treatment, lower baseline BCVA, lower age and smaller lesion size were identified as significant predictors of BCVA gain from baseline at month 24 (all p&lt;0.0001). However, the difference in mean BCVA gains at month 24 between treatment and control groups was similar for all baseline BCVA subgroups (\u226535\u2013&lt;55 letters, 21.9 letters; \u226555\u2013&lt;70 letters, 25.2 letters; \u226570\u2013&lt;85 letters, 19.3 letters).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Higher baseline BCVA is associated with lower BCVA gains but a greater likelihood of achieving good final BCVA &gt;69 letters due to smaller gains needed to achieve response. Visual benefits, including maintenance of visual acuity (VA), final VA achieved and relative gain compared with natural disease progression, should be considered when assessing treatment response in nAMD.<\/jats:p><\/jats:sec>","DOI":"10.1136\/bjophthalmol-2018-313682","type":"journal-article","created":{"date-parts":[[2019,9,28]],"date-time":"2019-09-28T02:05:51Z","timestamp":1569636351000},"page":"672-677","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Visual benefit versus visual gain: what is the effect of baseline covariants in the treatment arm relative to the control arm? A pooled analysis of ANCHOR and MARINA"],"prefix":"10.1136","volume":"104","clinical-trial-number":[{"clinical-trial-number":"nct00061594","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00056836","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0965-4890","authenticated-orcid":false,"given":"Adnan","family":"Tufail","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Margaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadhg","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"key-10.1136\/bjophthalmol-2018-313682-1","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/IAE.0b013e31827b6324","article-title":"Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study","volume":"33","author":"Cohen","year":"2013","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2018-313682-2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1055\/s-0029-1245203","article-title":"Response to ranibizumab therapy in neovascular AMD - an evaluation of good and bad responders","volume":"227","author":"Menghini","year":"2010","journal-title":"Klin Monbl Augenheilkd"},{"key":"key-10.1136\/bjophthalmol-2018-313682-3","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1517\/14712598.2012.660523","article-title":"Ranibizumab for age-related macular degeneration","volume":"12","author":"Dhoot","year":"2012","journal-title":"Expert Opin Biol Ther"},{"key":"key-10.1136\/bjophthalmol-2018-313682-4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bjophthalmol-2018-313682-5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2008.10.018","article-title":"Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the anchor study","volume":"116","author":"Brown","year":"2009","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-6","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bjophthalmol-2018-313682-7","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","article-title":"The restore study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema","volume":"118","author":"Mitchell","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-8","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","article-title":"Radiance: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia","volume":"121","author":"Wolf","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ophtha.2013.08.038","article-title":"Long-Term outcomes in patients with retinal vein occlusion treated with ranibizumab: the retain study","volume":"121","author":"Campochiaro","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-10","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 Mg or 2.0 Mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-11","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.ophtha.2013.11.031","article-title":"The neovascular age-related macular degeneration database: multicenter study of 92\u2009976 ranibizumab injections: report 1: visual acuity","volume":"121","year":"2014","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-12","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ophtha.2006.10.045","article-title":"Subgroup analysis of the marina study of ranibizumab in neovascular age-related macular degeneration","volume":"114","author":"Boyer","year":"2007","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-13","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ajo.2007.08.012","article-title":"Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year anchor results","volume":"144","author":"Kaiser","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1755-3768.2011.02268.x","article-title":"Predictors of 1-year visual outcome in neovascular age-related macular degeneration following intravitreal ranibizumab treatment","volume":"91","author":"Bloch","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-15","doi-asserted-by":"crossref","first-page":"no","DOI":"10.1111\/j.1442-9071.2010.02424.x","article-title":"Visual acuity outcomes in ranibizumab-treated neovascular age-related macular degeneration; stratified by baseline vision","volume":"355","author":"Shona","year":"2011","journal-title":"Clin Experiment Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000350238","article-title":"Three-Year visual outcome and injection frequency of intravitreal ranibizumab therapy for neovascular age-related macular degeneration","volume":"230","author":"Muniraju","year":"2013","journal-title":"Ophthalmologica"},{"key":"key-10.1136\/bjophthalmol-2018-313682-17","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/j.ophtha.2013.05.018","article-title":"A 4-year longitudinal study of 555 patients treated with ranibizumab for neovascular age-related macular degeneration","volume":"120","author":"Rasmussen","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-18","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/ICU.0000000000000050","article-title":"Long-Term longitudinal study of patients treated with ranibizumab for neovascular age-related macular degeneration","volume":"25","author":"Rasmussen","year":"2014","journal-title":"Curr Opin Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-19","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.ophtha.2011.12.016","article-title":"Horizon: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration","volume":"119","author":"Singer","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-20","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.ophtha.2012.02.002","article-title":"Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month Mont blanc study results","volume":"119","author":"Larsen","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ophtha.2010.07.011","article-title":"Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials","volume":"118","author":"Rosenfeld","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-22","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ophtha.2012.07.042","article-title":"Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration","volume":"120","author":"Ying","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-23","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/bjophthalmol-2014-306229","article-title":"Uk AMD EMR users group report V: benefits of initiating ranibizumab therapy for neovascular AMD in eyes with vision better than 6\/12","volume":"99","author":"Lee","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-24","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.ophtha.2013.07.053","article-title":"Prediction of age-related macular degeneration in the general population: the three continent AMD Consortium","volume":"120","author":"Buitendijk","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-25","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Martin","year":"2011","journal-title":"N Engl J Med"},{"key":"key-10.1136\/bjophthalmol-2018-313682-26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ajo.2007.10.004","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1","volume":"145","author":"Regillo","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-27","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ophtha.2010.09.004","article-title":"Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the excite study","volume":"118","author":"Schmidt-Erfurth","year":"2011","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-28","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ajo.2010.04.011","article-title":"Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2","volume":"150","author":"Abraham","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-30","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/IAE.0b013e318207d152","article-title":"One-Year results of a flexible regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections","volume":"31","author":"Arias","year":"2011","journal-title":"Retina"},{"key":"key-10.1136\/bjophthalmol-2018-313682-31","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.ajo.2007.01.028","article-title":"An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration","volume":"143","author":"Fung","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-32","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.ajo.2009.01.024","article-title":"A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study","volume":"148","author":"Lalwani","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-33","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ophtha.2012.07.026","article-title":"The secure study: long-term safety of ranibizumab 0.5 Mg in neovascular age-related macular degeneration","volume":"120","author":"Silva","year":"2013","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-34","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ajo.2015.01.032","article-title":"Macular atrophy progression and 7-year vision outcomes in subjects from the anchor, marina, and horizon studies: the seven-up study","volume":"159","author":"Bhisitkul","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-35","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1136\/bjophthalmol-2014-305327","article-title":"Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration","volume":"99","author":"Holz","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"key-10.1136\/bjophthalmol-2018-313682-36","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ophtha.2017.07.014","article-title":"Treat-and-Extend versus monthly regimen in neovascular age-related macular degeneration: results with ranibizumab from the trend study","volume":"125","author":"Silva","year":"2018","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-37","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.ophtha.2015.08.009","article-title":"Prospective trial of Treat-and-Extend versus monthly dosing for neovascular age-related macular degeneration: TREX-AMD 1-year results","volume":"122","author":"Wykoff","year":"2015","journal-title":"Ophthalmology"},{"key":"key-10.1136\/bjophthalmol-2018-313682-38","article-title":"Evaluating effects of switching anti-vascular endothelial growth factor drugs for age-related macular degeneration and diabetic macular edema","author":"Ferris","year":"2016","journal-title":"JAMA Ophthalmol"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjophthalmol-2018-313682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,26]],"date-time":"2020-09-26T08:59:30Z","timestamp":1601110770000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjophthalmol-2018-313682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,4,20]]},"published-print":{"date-parts":[[2020,5]]}},"alternative-id":["10.1136\/bjophthalmol-2018-313682"],"URL":"https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313682","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,27]]}}}